ArticleOncogene2006
Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development.
Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 65 citations in OpenAlex.
- Poor Adherence to Self-Applied Topical Drug Treatment Is a Common Source of Low Lesion Clearance in Patients with Actinic Keratosis-A Cross-Sectional Study.Journal of clinical medicine · 2023Article
- Pharmacological antagonism of EP2 receptor does not modify basal cardiovascular and respiratory function, blood cell counts, and bone morphology in animal models.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Article
- Thymoquinone Suppresses Migration of Human Renal Carcinoma Caki-1 Cells through Inhibition of the PGEBiomolecules & therapeutics · 2021Article
- Review
- New insights into the functions of Cox-2 in skin and esophageal malignancies.Experimental & molecular medicine · 2020Review
- Treatment of actinic keratosis through inhibition of cyclooxygenase-2: Potential mechanism of action of diclofenac sodium 3% in hyaluronic acid 2.5.Dermatologic therapy · 2019Review
- Peripherally Restricted, Highly Potent, Selective, Aqueous-Soluble EP2 Antagonist with Anti-Inflammatory Properties.Molecular pharmaceutics · 2018Article
- Novel water-soluble lignin derivative BP-Cx-1: identification of components and screening of potential targetsOncotarget · 2018Article
- Cyclooxygenase in Cancer Prevention and Treatments for Actinic Keratosis.Dermatology and therapy · 2017Review
- Decursinol angelate inhibits PGE2-induced survival of the human leukemia HL-60 cell line via regulation of the EP2 receptor and NFκB pathway.Cancer biology & therapy · 2016Article
- Review
- EP2 Induces p38 Phosphorylation via the Activation of Src in HEK 293 Cells.Biomolecules & therapeutics · 2015Article
- Prostaglandin F2α receptor (FP) signaling regulates Bmp signaling and promotes chondrocyte differentiation.Biochimica et biophysica acta · 2015Article
- The tumor promoting activity of the EP4 receptor for prostaglandin E2 in murine skin.Molecular oncology · 2014Article
- Development of second generation EP2 antagonists with high selectivity.European journal of medicinal chemistry · 2014Article
- Prostanoid receptor EP2 as a therapeutic target.Journal of medicinal chemistry · 2014Review
- Lead optimization studies of cinnamic amide EP2 antagonists.Journal of medicinal chemistry · 2014Article
- Does prostaglandin D2 hold the cure to male pattern baldness?Experimental dermatology · 2014Review
- Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection.Trends in pharmacological sciences · 2013Review
- Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation.The Journal of pharmacology and experimental therapeutics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
We previously showed that the EP2 knockout mice were resistant to chemically induced skin carcinogenesis. The purpose of this study was to investigate the role of the overexpression of the EP2 receptor in mouse skin carcinogenesis. To determine the effect of overexpression of EP2, we used EP2 transgenic (TG) mice and wild-type (WT) mice in a DMBA (7,12-dimethylbenz[alpha]anthracene)/TPA (12-O-tetradecanoylphorbol-13-acetate) two-stage carcinogenesis protocol. EP2 TG mice developed significantly more tumors compared with WT mice. Overexpression of the EP2 receptor increased TPA-induced keratinocyte proliferation both in vivo and in vitro. In addition, the epidermis of EP2 TG mice 48 h after topical TPA treatment was significantly thicker compared to that of WT mice. EP2 TG mice showed significantly increased cyclic adenosine monophosphate levels in the epidermis after prostaglandin E2 (PGE2) treatment. The inflammatory response to TPA was increased in EP2 TG mice, as demonstrated by an increased number of macrophages in the dermis. Tumors and 7 x TPA-treated and DMBA-TPA-treated (6 weeks) skins from EP2 TG mice produced more blood vessels than those of WT mice as determined by CD-31 immunostaining. Vascular endothelial growth factor (VEGF) protein expression was significantly increased in squamous cell carcinoma (SCC) samples from EP2 TG mice compared that of WT mice. There was, however, no difference in the number of apoptotic cells in tumors from WT and EP2 TG mice. Together, our results suggest that the overexpression of the EP2 receptor plays a significant role in the protumorigenic action of PGE2 in mouse skin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.